Is long-acting repeatable octreotide an effective primary therapy for patients with acromegaly?

被引：0
|
作者：
Vivien S Bonert
机构：
[1] David Geffen School of Medicine,VS Bonert is a Professor in the Department of Medicine at Cedars Sinai Medical Center
[2] University of California,undefined
[3] Los Angeles,undefined
[4] CA,undefined
[5] USA.,undefined
来源：
Nature Clinical Practice Endocrinology & Metabolism | 2008年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：18 / 19
页数：1
相关论文
共 50 条
  • [31] A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib
    Hironori Kitade
    Koushiro Ohtsubo
    Kengo Hokkoku
    Mitsue Mori
    Robert Yoshiyuki Osamura
    Hiroshi Sakuma
    Masuo Nakai
    Seiji Yano
    International Cancer Conference Journal, 2019, 8 : 24 - 28
  • [32] A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib
    Kitade, Hironori
    Ohtsubo, Koushiro
    Hokkoku, Kengo
    Mori, Mitsue
    Osamura, Robert Yoshiyuki
    Sakuma, Hiroshi
    Nakai, Masuo
    Yano, Seiji
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2019, 8 (01) : 24 - 28
  • [33] Long-acting octreotide is effective in the treatment of portal hypertensive colopathy
    Branco, Joana C.
    Carvalho, Rita
    Alberto, Sara E.
    Reis, Jorge
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (08): : 536 - 537
  • [34] Long acting somatostatin analogue octreotide treatment of patients with acromegaly
    Magony, S
    Julesz, J
    Gardi, J
    Laczi, F
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152
  • [35] Octreotide as primary therapy for acromegaly
    Newman, CB
    Melmed, S
    George, A
    Torigian, D
    Duhaney, M
    Snyder, P
    Young, W
    Klibanski, A
    Molitch, ME
    Gagel, R
    Sheeler, L
    Cook, D
    Malarkey, W
    Jackson, I
    Vance, ML
    Barkan, A
    Frohman, L
    Kleinberg, DL
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09): : 3034 - 3040
  • [36] PHARMACOKINETICS OF THE LONG-ACTING SOMATOSTATIN ANALOG OCTREOTIDE (SMS 201-995) IN ACROMEGALY
    NICHOLLS, J
    WYNICK, D
    DOMIN, J
    SANDLER, LM
    BLOOM, SR
    CLINICAL ENDOCRINOLOGY, 1990, 32 (05) : 545 - 550
  • [37] Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study
    Shen, Ming
    Shou, Xuefei
    Wang, Yongfei
    Zhang, Zhaoyun
    Wu, Jinsong
    Mao, Ying
    Li, Shiqi
    Zhao, Yao
    ENDOCRINE JOURNAL, 2010, 57 (12) : 1035 - 1044
  • [38] Effects of Long-acting Release Octreotide on Glucose Homeostasis in Acromegaly Patients after Trans-Sphenoidal Surgery
    Chen, H. -S.
    Wu, T-E.
    Jap, T. -S.
    Hsiao, L. -C.
    Lin, H. -D.
    Lee, S. -H.
    Lin, S. -H.
    HORMONE AND METABOLIC RESEARCH, 2011, 43 (06) : 433 - 439
  • [39] Octreotide Long-Acting Repeatable among Elderly Patients with Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data
    Shen, Chan
    Shih, Ya-Chen Tina
    Xu, Ying
    Yao, James C.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (11) : 1656 - 1665
  • [40] Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract
    Orsi, P
    Guatti-Zuliani, C
    Okolicsanyi, L
    DIGESTIVE AND LIVER DISEASE, 2001, 33 (04) : 330 - 334
12345